PhagoMed

Vienna, Austria Founded: 2016 • Age: 10 yrs Acquired By BioNTech
Alternatives to antibiotics are developed via phage therapy expertise.
Request Access

About PhagoMed

PhagoMed is a company based in Vienna (Austria) founded in 2016 by Jörg schierholz, Burkhard Wippermann, Alexander Belcredi, and Andrej Trampuz was acquired by BioNTech in November 2021.. PhagoMed has raised $1.7 million across 2 funding rounds from investors including BioNTech. PhagoMed operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.

  • Headquarter Vienna, Austria
  • Founders Jörg schierholz, Burkhard Wippermann, Alexander Belcredi, Andrej Trampuz
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.7 M (USD)

    in 2 rounds

  • Latest Funding Round
    $1.7 M (USD), Seed

    Jul 01, 2019

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    BioNTech

    (Nov 09, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of PhagoMed

PhagoMed has successfully raised a total of $1.7M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.7 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Seed — $1.7M
  • First Round
  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2019 Amount Seed - PhagoMed Valuation

investors

Jun, 2018 Amount Grant - PhagoMed Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in PhagoMed

PhagoMed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include BioNTech. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Immunotherapeutics for cancer and other diseases are developed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by PhagoMed

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - PhagoMed

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Phagomed Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of PhagoMed

PhagoMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of pharmaceuticals and vaccines for various therapeutic areas
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Yeast cells are genetically engineered to produce medicinal products.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
CRISPR-engineered cell and gene therapies are developed for research applications.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Phagomed

Frequently Asked Questions about PhagoMed

When was PhagoMed founded?

PhagoMed was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is PhagoMed located?

PhagoMed is headquartered in Vienna, Austria.

Is PhagoMed a funded company?

PhagoMed is a funded company, having raised a total of $1.7M across 2 funding rounds to date.

What does PhagoMed do?

PhagoMed is a developing a phage drug development platform through which they are advancing a portfolio of candidates currently at the preclinical stage. The company claims that phage therapy is a better alternative to antibiotics due to the issue of resistance, their insufficient effectiveness against biofilms and also due to their side effects. In exceptional and severe cases the company is exploring experimental treatment options as per the Helsinki protocol for wound and periprosthetic infections. The company is looking for partners to establish preclinical proof of their technology.

Who are the top competitors of PhagoMed?

PhagoMed's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

Who are PhagoMed's investors?

PhagoMed has 1 investor. Key investors include BioNTech.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available